TruDiagnostic has been awarded a Small Business Innovation Research (SBIR) grant by the National Institutes of Health (NIH) to advance development of its W-Function Epigenomic Roadmap, the company says.
The funding will support TruDiagnostic’s effort to create a next-generation framework that models how DNA methylation patterns shift over time, rather than relying on static snapshots, in order to improve prediction, prevention, and early detection of chronic disease.
According to TruDiagnostic, the roadmap will leverage its longitudinal methylation database to distinguish causal epigenetic changes from random variation. The aim is to generate more accurate health forecasts, identify earlier intervention points, and reveal novel therapeutic targets.
The company plans to initially apply the model to cardiovascular disease, type 2 diabetes, and mortality risk, with future expansion into other chronic conditions. The firm claims that upon successful validation, the roadmap could support more dynamic health tracking, personalized treatment, and accelerate epigenetic marker–driven drug development.
TruDiagnostic, a CLIA-certified laboratory and health data company, notes it already maintains a large private DNA methylation database and conducts epigenetic testing and research.
